(Lys9)GLP-1 lacks insulinotropic activity but acts as a potent novel GLP-1 receptor antagonist in vivo.

F.P.M. O'Harte, Brian Green, V.A. Gault, N. Irwin, Mark Mooney, Patrick Harriott, B. Greer, P.R. Flatt

Research output: Contribution to journalMeeting abstract

22 Citations (Scopus)
Original languageEnglish
Pages (from-to)P26
JournalDiabetic Medicine
Volume21
Issue numberS2
Publication statusPublished - 2004

Cite this

O'Harte, F. P. M., Green, B., Gault, V. A., Irwin, N., Mooney, M., Harriott, P., Greer, B., & Flatt, P. R. (2004). (Lys9)GLP-1 lacks insulinotropic activity but acts as a potent novel GLP-1 receptor antagonist in vivo. Diabetic Medicine, 21(S2), P26.